AxoGen, Inc. Logo

AxoGen, Inc.

0HKD.L

(0.0)
Stock Price

12,49 USD

-8.99% ROA

-17.3% ROE

-35.97x PER

Market Cap.

596.523.578,00 USD

51% DER

0% Yield

-9.53% NPM

AxoGen, Inc. Stock Analysis

AxoGen, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

AxoGen, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

AxoGen, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

AxoGen, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

AxoGen, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

AxoGen, Inc. Revenue
Year Revenue Growth
1987 4.700.000
1988 5.800.000 18.97%
1989 6.400.000 9.38%
1990 6.800.000 5.88%
1991 8.000.000 15%
1992 8.100.000 1.23%
1993 9.200.000 11.96%
1994 10.700.000 14.02%
1995 14.100.000 24.11%
1996 13.100.000 -7.63%
1997 12.300.000 -6.5%
1998 12.900.000 4.65%
1999 12.300.000 -4.88%
2000 14.596.346 15.73%
2001 15.928.832 8.37%
2002 6.852.091 -132.47%
2003 7.236.935 5.32%
2004 1.065.000 -579.52%
2005 443.352 -140.22%
2006 126.660 -250.03%
2007 100.431 -26.12%
2008 72.711 -38.12%
2009 24.911.376 99.71%
2010 91.273 -27193.26%
2011 4.849.470 98.12%
2012 7.691.704 36.95%
2013 10.947.361 29.74%
2014 16.817.403 34.9%
2015 27.331.092 38.47%
2016 41.107.538 33.51%
2017 60.426.395 31.97%
2018 83.937.000 28.01%
2019 106.712.000 21.34%
2020 112.300.000 4.98%
2021 127.358.000 11.82%
2022 138.584.000 8.1%
2023 165.084.000 16.05%
2023 159.012.000 -3.82%
2024 191.648.000 17.03%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

AxoGen, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1987 0
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 1.400.000 100%
1995 1.900.000 26.32%
1996 1.900.000 0%
1997 1.500.000 -26.67%
1998 1.000.000 -50%
1999 1.200.000 16.67%
2000 1.094.808 -9.61%
2001 919.786 -19.03%
2002 491.515 -87.13%
2003 424.457 -15.8%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 697.355 100%
2012 1.427.211 51.14%
2013 2.125.476 32.85%
2014 3.033.325 29.93%
2015 3.237.171 6.3%
2016 4.212.023 23.14%
2017 6.699.120 37.13%
2018 11.773.000 43.1%
2019 17.514.000 32.78%
2020 17.846.000 1.86%
2021 24.177.000 26.19%
2022 27.158.000 10.98%
2023 27.956.000 2.85%
2023 28.333.000 1.33%
2024 26.632.000 -6.39%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

AxoGen, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1987 0
1988 1.900.000 100%
1989 2.100.000 9.52%
1990 2.100.000 0%
1991 1.900.000 -10.53%
1992 2.100.000 9.52%
1993 2.700.000 22.22%
1994 1.800.000 -50%
1995 3.800.000 52.63%
1996 3.700.000 -2.7%
1997 2.800.000 -32.14%
1998 3.100.000 9.68%
1999 4.700.000 34.04%
2000 6.916.906 32.05%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 4.315.604 100%
2012 5.220.599 17.34%
2013 5.715.119 8.65%
2014 6.948.890 17.75%
2015 8.422.866 17.5%
2016 10.132.624 16.87%
2017 14.731.105 31.22%
2018 23.124.000 36.3%
2019 31.305.000 26.13%
2020 26.396.000 -18.6%
2021 32.338.000 18.37%
2022 36.758.000 12.02%
2023 35.340.000 -4.01%
2023 34.943.000 -1.14%
2024 37.668.000 7.23%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

AxoGen, Inc. EBITDA
Year EBITDA Growth
1987 300.000
1988 1.000.000 70%
1989 700.000 -42.86%
1990 900.000 22.22%
1991 1.100.000 18.18%
1992 1.300.000 15.38%
1993 1.000.000 -30%
1994 1.200.000 16.67%
1995 800.000 -50%
1996 400.000 -100%
1997 3.300.000 87.88%
1998 300.000 -1000%
1999 -1.000.000 130%
2000 -2.010.165 50.25%
2001 -6.865.214 70.72%
2002 -1.872.040 -266.72%
2003 -673.706 -177.87%
2004 87.683 868.34%
2005 -306.480 128.61%
2006 -371.918 17.59%
2007 -777.648 52.17%
2008 -1.033.666 24.77%
2009 15.978.790 106.47%
2010 -1.828.758 973.75%
2011 -6.695.342 72.69%
2012 -7.463.135 10.29%
2013 -9.419.981 20.77%
2014 -9.598.747 1.86%
2015 -8.990.926 -6.76%
2016 -7.712.999 -16.57%
2017 -7.415.456 -4.01%
2018 -19.677.000 62.31%
2019 -26.218.000 24.95%
2020 -19.760.000 -32.68%
2021 -20.953.000 5.69%
2022 -25.084.000 16.47%
2023 -11.204.000 -123.88%
2023 -15.909.000 29.57%
2024 6.528.000 343.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

AxoGen, Inc. Gross Profit
Year Gross Profit Growth
1987 700.000
1988 3.200.000 78.13%
1989 3.100.000 -3.23%
1990 3.000.000 -3.33%
1991 3.300.000 9.09%
1992 3.600.000 8.33%
1993 3.900.000 7.69%
1994 4.600.000 15.22%
1995 6.600.000 30.3%
1996 6.100.000 -8.2%
1997 5.400.000 -12.96%
1998 4.500.000 -20%
1999 5.000.000 10%
2000 6.029.241 17.07%
2001 5.422.601 -11.19%
2002 1.639.658 -230.72%
2003 1.741.623 5.85%
2004 1.065.000 -63.53%
2005 443.352 -140.22%
2006 126.660 -250.03%
2007 100.431 -26.12%
2008 72.711 -38.12%
2009 24.911.376 99.71%
2010 91.273 -27193.26%
2011 2.422.926 96.23%
2012 5.729.827 57.71%
2013 8.507.543 32.65%
2014 13.375.220 36.39%
2015 22.482.696 40.51%
2016 34.640.288 35.1%
2017 51.114.810 32.23%
2018 71.014.000 28.02%
2019 89.363.000 20.53%
2020 90.719.000 1.49%
2021 104.427.000 13.13%
2022 114.437.000 8.75%
2023 132.912.004 13.9%
2023 127.874.000 -3.94%
2024 141.380.000 9.55%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

AxoGen, Inc. Net Profit
Year Net Profit Growth
1987 500.000
1988 900.000 44.44%
1989 600.000 -50%
1990 400.000 -50%
1991 900.000 55.56%
1992 1.000.000 10%
1993 700.000 -42.86%
1994 600.000 -16.67%
1995 200.000 -200%
1996 -600.000 133.33%
1997 -2.300.000 73.91%
1998 -400.000 -475%
1999 -1.700.000 76.47%
2000 -2.859.276 40.54%
2001 1.343.492 312.82%
2002 -2.602.781 151.62%
2003 -1.281.761 -103.06%
2004 2.296.679 155.81%
2005 -530.612 532.84%
2006 -367.182 -44.51%
2007 -748.980 50.98%
2008 -1.040.709 28.03%
2009 15.046.332 106.92%
2010 -1.316.299 1243.08%
2011 -9.219.220 85.72%
2012 -9.417.958 2.11%
2013 -14.556.885 35.3%
2014 -17.710.476 17.81%
2015 -13.356.425 -32.6%
2016 -14.411.144 7.32%
2017 -10.445.462 -37.97%
2018 -22.397.000 53.36%
2019 -29.122.000 23.09%
2020 -24.802.000 -17.42%
2021 -28.063.000 11.62%
2022 -27.335.000 -2.66%
2023 -16.356.000 -67.13%
2023 -21.716.000 24.68%
2024 -7.684.000 -182.61%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

AxoGen, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1987 0
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 -1 0%
1998 0 0%
1999 0 0%
2000 -1 0%
2001 0 0%
2002 -1 0%
2003 0 0%
2004 1 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 4 100%
2010 -2 400%
2011 -2 50%
2012 -1 0%
2013 -1 100%
2014 -1 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 -1 0%
2019 -1 0%
2020 -1 0%
2021 -1 0%
2022 -1 0%
2023 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

AxoGen, Inc. Free Cashflow
Year Free Cashflow Growth
1990 400.000
1991 700.000 42.86%
1992 400.000 -75%
1993 900.000 55.56%
1994 -1.800.000 150%
1995 -1.400.000 -28.57%
1996 -200.000 -600%
1997 -100.000 -100%
1998 1.100.000 109.09%
1999 -600.000 283.33%
2000 -1.696.307 64.63%
2001 -3.295.028 48.52%
2002 -776.091 -324.57%
2003 -49.301 -1474.19%
2004 804.289 106.13%
2005 -709.618 213.34%
2006 -28.793 -2364.55%
2007 -466.947 93.83%
2008 -500.077 6.62%
2009 15.433.259 103.24%
2010 -2.470.357 724.74%
2011 -7.168.756 65.54%
2012 -8.789.142 18.44%
2013 -10.688.723 17.77%
2014 -11.045.106 3.23%
2015 -13.607.337 18.83%
2016 -12.393.997 -9.79%
2017 -10.529.817 -17.7%
2018 -24.465.000 56.96%
2019 -141.508.000 82.71%
2020 -32.223.000 -339.15%
2021 -41.805.000 22.92%
2022 -37.319.000 -12.02%
2023 -20.634.000 -80.86%
2023 -2.064.000 -899.71%
2024 2.933.000 170.37%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

AxoGen, Inc. Operating Cashflow
Year Operating Cashflow Growth
1990 600.000
1991 1.300.000 53.85%
1992 1.100.000 -18.18%
1993 1.400.000 21.43%
1994 300.000 -366.67%
1995 100.000 -200%
1996 200.000 50%
1997 100.000 -100%
1998 1.500.000 93.33%
1999 -200.000 850%
2000 -1.271.859 84.27%
2001 -2.923.122 56.49%
2002 -755.021 -287.16%
2003 -27.300 -2665.64%
2004 878.839 103.11%
2005 -709.618 223.85%
2006 -28.793 -2364.55%
2007 -466.947 93.83%
2008 -470.164 0.68%
2009 15.441.941 103.04%
2010 -2.429.661 735.56%
2011 -7.079.290 65.68%
2012 -8.661.858 18.27%
2013 -10.444.758 17.07%
2014 -10.451.059 0.06%
2015 -13.051.819 19.93%
2016 -11.204.442 -16.49%
2017 -9.237.599 -21.29%
2018 -17.862.000 48.28%
2019 -19.872.000 10.11%
2020 -9.626.000 -106.44%
2021 -13.405.000 28.19%
2022 -16.066.000 16.56%
2023 -5.716.000 -181.07%
2023 1.626.000 451.54%
2024 4.165.000 60.96%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

AxoGen, Inc. Capital Expenditure
Year Capital Expenditure Growth
1990 200.000
1991 600.000 66.67%
1992 700.000 14.29%
1993 500.000 -40%
1994 2.100.000 76.19%
1995 1.500.000 -40%
1996 400.000 -275%
1997 200.000 -100%
1998 400.000 50%
1999 400.000 0%
2000 424.448 5.76%
2001 371.906 -14.13%
2002 21.070 -1665.1%
2003 22.001 4.23%
2004 74.550 70.49%
2005 0 0%
2006 0 0%
2007 0 0%
2008 29.913 100%
2009 8.682 -244.54%
2010 40.696 78.67%
2011 89.466 54.51%
2012 127.284 29.71%
2013 243.965 47.83%
2014 594.047 58.93%
2015 555.518 -6.94%
2016 1.189.555 53.3%
2017 1.292.218 7.94%
2018 6.603.000 80.43%
2019 121.636.000 94.57%
2020 22.597.000 -438.28%
2021 28.400.000 20.43%
2022 21.253.000 -33.63%
2023 14.918.000 -42.47%
2023 3.690.000 -304.28%
2024 1.232.000 -199.51%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

AxoGen, Inc. Equity
Year Equity Growth
1987 5.400.000
1988 5.800.000 6.9%
1989 6.500.000 10.77%
1990 6.900.000 5.8%
1991 7.700.000 10.39%
1992 9.400.000 18.09%
1993 10.300.000 8.74%
1994 10.800.000 4.63%
1995 11.200.000 3.57%
1996 10.900.000 -2.75%
1997 8.800.000 -23.86%
1998 9.700.000 9.28%
1999 7.500.000 -29.33%
2000 4.719.816 -58.9%
2001 3.540.199 -33.32%
2002 966.799 -266.18%
2003 -153.768 728.74%
2004 2.282.082 106.74%
2005 1.663.965 -37.15%
2006 1.296.783 -28.31%
2007 898.815 -44.28%
2008 313.187 -186.99%
2009 11.061.169 97.17%
2010 10.029.128 -10.29%
2011 6.071.471 -65.18%
2012 -2.829.441 314.58%
2013 136.633 2170.83%
2014 -11.245.680 101.21%
2015 8.195.591 237.22%
2016 14.921.149 45.07%
2017 25.182.035 40.75%
2018 146.982.000 82.87%
2019 132.153.000 -11.22%
2020 123.149.000 -7.31%
2021 112.550.000 -9.42%
2022 100.999.000 -11.44%
2023 97.810.000 -3.26%
2023 95.665.000 -2.24%
2024 95.687.000 0.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

AxoGen, Inc. Assets
Year Assets Growth
1987 6.700.000
1988 6.900.000 2.9%
1989 8.200.000 15.85%
1990 8.400.000 2.38%
1991 8.400.000 0%
1992 9.900.000 15.15%
1993 11.000.000 10%
1994 12.400.000 11.29%
1995 12.700.000 2.36%
1996 12.300.000 -3.25%
1997 11.800.000 -4.24%
1998 11.300.000 -4.42%
1999 10.100.000 -11.88%
2000 8.474.549 -19.18%
2001 6.350.154 -33.45%
2002 4.150.207 -53.01%
2003 2.690.650 -54.25%
2004 2.803.134 4.01%
2005 1.824.825 -53.61%
2006 1.514.657 -20.48%
2007 1.099.989 -37.7%
2008 524.243 -109.82%
2009 16.808.435 96.88%
2010 10.143.477 -65.71%
2011 12.495.042 18.82%
2012 20.230.563 38.24%
2013 27.684.270 26.92%
2014 16.400.789 -68.8%
2015 37.546.053 56.32%
2016 46.360.478 19.01%
2017 58.874.698 21.26%
2018 160.173.000 63.24%
2019 154.643.000 -3.58%
2020 201.381.000 23.21%
2021 208.024.000 3.19%
2022 195.387.000 -6.47%
2023 194.630.000 -0.39%
2023 196.827.000 1.12%
2024 188.932.000 -4.18%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

AxoGen, Inc. Liabilities
Year Liabilities Growth
1987 1.300.000
1988 1.100.000 -18.18%
1989 1.700.000 35.29%
1990 1.500.000 -13.33%
1991 700.000 -114.29%
1992 500.000 -40%
1993 700.000 28.57%
1994 1.600.000 56.25%
1995 1.500.000 -6.67%
1996 1.400.000 -7.14%
1997 3.000.000 53.33%
1998 1.600.000 -87.5%
1999 2.600.000 38.46%
2000 3.754.733 30.75%
2001 2.809.955 -33.62%
2002 3.183.408 11.73%
2003 2.844.418 -11.92%
2004 521.052 -445.9%
2005 160.860 -223.92%
2006 217.874 26.17%
2007 201.174 -8.3%
2008 211.056 4.68%
2009 5.747.266 96.33%
2010 114.349 -4926.07%
2011 6.423.571 98.22%
2012 23.060.004 72.14%
2013 27.547.637 16.29%
2014 27.646.469 0.36%
2015 29.350.462 5.81%
2016 31.439.329 6.64%
2017 33.692.663 6.69%
2018 13.191.000 -155.42%
2019 22.490.000 41.35%
2020 78.232.000 71.25%
2021 95.474.000 18.06%
2022 94.388.000 -1.15%
2023 96.820.000 2.51%
2023 101.162.000 4.29%
2024 93.245.000 -8.49%

AxoGen, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.97
Net Income per Share
-0.38
Price to Earning Ratio
-35.97x
Price To Sales Ratio
3.44x
POCF Ratio
-88.98
PFCF Ratio
-39.92
Price to Book Ratio
6.22
EV to Sales
3.69
EV Over EBITDA
-128.2
EV to Operating CashFlow
-95.78
EV to FreeCashFlow
-42.86
Earnings Yield
-0.03
FreeCashFlow Yield
-0.03
Market Cap
0,60 Bil.
Enterprise Value
0,64 Bil.
Graham Number
4.32
Graham NetNet
-0.76

Income Statement Metrics

Net Income per Share
-0.38
Income Quality
0.4
ROE
-0.17
Return On Assets
-0.09
Return On Capital Employed
-0.07
Net Income per EBT
1
EBT Per Ebit
1.35
Ebit per Revenue
-0.07
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0.21
Research & Developement to Revenue
0.16
Stock Based Compensation to Revenue
0.08
Gross Profit Margin
0.78
Operating Profit Margin
-0.07
Pretax Profit Margin
-0.1
Net Profit Margin
-0.1

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.15
Free CashFlow per Share
-0.34
Capex to Operating CashFlow
-1.23
Capex to Revenue
0.05
Capex to Depreciation
1.14
Return on Invested Capital
-0.1
Return on Tangible Assets
-0.09
Days Sales Outstanding
52.92
Days Payables Outstanding
205.25
Days of Inventory on Hand
265.42
Receivables Turnover
6.9
Payables Turnover
1.78
Inventory Turnover
1.38
Capex per Share
0.19

Balance Sheet

Cash per Share
0,62
Book Value per Share
2,19
Tangible Book Value per Share
2.08
Shareholders Equity per Share
2.19
Interest Debt per Share
1.28
Debt to Equity
0.51
Debt to Assets
0.26
Net Debt to EBITDA
-8.78
Current Ratio
3.51
Tangible Asset Value
0,09 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
165517000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,02 Bil.
Average Payables
0,02 Bil.
Average Inventory
27825500
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

AxoGen, Inc. Dividends
Year Dividends Growth
2022 0

AxoGen, Inc. Profile

About AxoGen, Inc.

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

CEO
Ms. Karen Zaderej
Employee
426
Address
13631 Progress Boulevard
Alachua, 32615

AxoGen, Inc. Executives & BODs

AxoGen, Inc. Executives & BODs
# Name Age
1 Dr. Ivica Ducic M.D., Ph.D.
Chief Medical Officer
70
2 Mr. Jens Schroeder Kemp
Chief Marketing Officer
70
3 Mr. Marc A. Began
Executive Vice President, General Counsel & Chief Compliance Officer
70
4 Ms. Doris Quackenbush
Vice President of Sales
70
5 Ms. Karen Zaderej
Advisor
70
6 Mr. Erick DeVinney
Chief Innovation Officer
70
7 Mr. Todd Puckett
Vice President of Operations
70
8 Mr. Harold D. Tamayo
Vice President of Finance & Investor Relations
70

AxoGen, Inc. Competitors